(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 September 2011 (15.09.2011)

PCT

(10) International Publication Number
WO 2011/110612 A1

(51) International Patent Classification:
C07D 213/75 (2006.01) *A61K 31/44* (2006.01)
C07D 401/12 (2006.01) *A61K 31/4436* (2006.01)
C07D 401/14 (2006.01) *A61K 31/496* (2006.01)
C07D 409/12 (2006.01) *A61P 25/28* (2006.01)
C07D 417/12 (2006.01) *A61P 29/00* (2006.01)
A61K 31/4418 (2006.01) *A61P 9/00* (2006.01)
A61K 31/4545 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:
PCT/EP2011/053574

(22) International Filing Date:
10 March 2011 (10.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/339,866 10 March 2010 (10.03.2010) US

(71) Applicant *(for all designated States except US)*: **INGENIUM PHARMACEUTICALS GMBH** [DE/DE]; Fraunhoferstrasse 13, 82152 Martinsried (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HEISER, Ulrich** [DE/DE]; Franz-Schubert-Strasse 5, 06108 Halle / Saale (DE). **NIESTROJ, André J.** [DE/DE]; Thaelmannplatz 1, 06193 Sennewitz (DE). **ZEITLMANN, Lutz** [DE/DE]; Jutastrasse 15, 80636 Muenchen (DE).

(74) Agent: **HOFFMANN, Matthias**; Probiodrug AG, Weinbergweg 22, 06120 Halle / Saale (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: INHIBITORS OF PROTEIN KINASES



(I)

(57) Abstract: Compounds of general Formula (I) wherein R^1, R^2, R^3, R^a, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

WO 2011/110612 A1